Correction to: Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3)

Detalles Bibliográficos
Autores principales: Blauvelt, Andrew, Papp, Kim A., Griffiths, Christopher E. M., Puig, Luis, Weisman, Jamie, Dutronc, Yves, Kerr, Lisa Farmer, Ilo, Dapo, Mallbris, Lotus, Augustin, Matthias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2018
Materias:
Correction
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5945710/
https://www.ncbi.nlm.nih.gov/pubmed/29600394
http://dx.doi.org/10.1007/s40257-018-0353-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5945710/
https://www.ncbi.nlm.nih.gov/pubmed/29600394
http://dx.doi.org/10.1007/s40257-018-0353-x

Ejemplares similares